Johnson & Johnson Revenue 2010-2022 | JNJ

Johnson & Johnson annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Johnson & Johnson revenue for the quarter ending September 30, 2022 was $23.791B, a 1.94% increase year-over-year.
  • Johnson & Johnson revenue for the twelve months ending September 30, 2022 was $96.041B, a 5.02% increase year-over-year.
  • Johnson & Johnson annual revenue for 2021 was $93.775B, a 13.55% increase from 2020.
  • Johnson & Johnson annual revenue for 2020 was $82.584B, a 0.64% increase from 2019.
  • Johnson & Johnson annual revenue for 2019 was $82.059B, a 0.59% increase from 2018.
Johnson & Johnson Annual Revenue
(Millions of US $)
2021 $93,775
2020 $82,584
2019 $82,059
2018 $81,581
2017 $76,450
2016 $71,890
2015 $70,074
2014 $74,331
2013 $71,312
2012 $67,224
2011 $65,030
2010 $61,587
2009 $61,897
Johnson & Johnson Quarterly Revenue
(Millions of US $)
2022-09-30 $23,791
2022-06-30 $24,020
2022-03-31 $23,426
2021-12-31 $24,804
2021-09-30 $23,338
2021-06-30 $23,312
2021-03-31 $22,321
2020-12-31 $22,475
2020-09-30 $21,082
2020-06-30 $18,336
2020-03-31 $20,691
2019-12-31 $20,747
2019-09-30 $20,729
2019-06-30 $20,562
2019-03-31 $20,021
2018-12-31 $20,394
2018-09-30 $20,348
2018-06-30 $20,830
2018-03-31 $20,009
2017-12-31 $20,195
2017-09-30 $19,650
2017-06-30 $18,839
2017-03-31 $17,766
2016-12-31 $18,106
2016-09-30 $17,820
2016-06-30 $18,482
2016-03-31 $17,482
2015-12-31 $17,811
2015-09-30 $17,102
2015-06-30 $17,787
2015-03-31 $17,374
2014-12-31 $18,254
2014-09-30 $18,467
2014-06-30 $19,495
2014-03-31 $18,115
2013-12-31 $18,355
2013-09-30 $17,575
2013-06-30 $17,877
2013-03-31 $17,505
2012-12-31 $17,558
2012-09-30 $17,052
2012-06-30 $16,475
2012-03-31 $16,139
2011-12-31 $16,255
2011-09-30 $16,005
2011-06-30 $16,597
2011-03-31 $16,173
2010-12-31 $15,644
2010-09-30 $14,982
2010-06-30 $15,330
2010-03-31 $15,631
2009-12-31 $16,551
2009-09-30 $15,081
2009-06-30 $15,239
2009-03-31 $15,026
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $463.208B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $353.438B 44.60
AbbVie (ABBV) United States $292.507B 12.13
Novo Nordisk (NVO) Denmark $283.414B 37.16
Pfizer (PFE) United States $282.013B 7.71
Merck (MRK) United States $279.122B 14.37
Novartis AG (NVS) Switzerland $202.962B 15.29